How will the NRDL listing impact BeiGene's revenue?

The NRDL listing is a major catalyst for revenue growth. By being included in the national reimbursement system, these drugs will become more affordable and accessible to a much larger patient population in China, leading to increased sales volume and market penetration.

What are the specific indications covered by the NRDL listing for these drugs?

Tislelizumab is covered for classical Hodgkin’s lymphoma and specific types of urothelial carcinoma. BRUKINSA® (zanubrutinib) is covered for mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. XGEVA® (denosumab) is covered for giant cell tumor of the bone.

Where can I find the detailed financial results for Q4 2020?

The detailed financial results for the three months and year ended December 31, 2020, are referenced in Exhibit 99.1 of this Form 8-K, which is a press release issued by BeiGene, Ltd. on February 25, 2021. Investors should refer to that press release for specific financial figures.

ONC/BEIGF 8-K: Earnings & Results & Regulation FD

Q: What is the most significant news for investors in this filing?

The most significant news for investors is the inclusion of BeiGene's key oncology drugs, Tislelizumab, BRUKINSA®, and XGEVA®, on China's National Reimbursement Drug List (NRDL) effective March 1, 2021. This is a critical step that will broaden patient access and is expected to significantly drive commercial success in the large Chinese market.

Summary

BeiGene, Ltd. (ONC) announced its financial results for the fourth quarter and full year ended December 31, 2020, via an 8-K filing on February 25, 2021. While the specific financial figures are not detailed in the provided excerpt, the report primarily highlights significant developments regarding the inclusion of key BeiGene medicines on China's National Reimbursement Drug List (NRDL), effective March 1, 2021. This inclusion is a crucial development for the company, as it will facilitate broader patient access and potentially drive significant revenue growth in the Chinese market for these innovative therapies. The NRDL listing covers Tislelizumab for specific types of lymphoma and urothelial carcinoma, BRUKINSA® (zanubrutinib) for mantle cell lymphoma and chronic lymphocytic leukemia, and XGEVA® (denosumab) for bone tumors. The negotiated payment standards for these drugs are now established, marking a pivotal step for commercialization and market penetration in China. The filing also references updates on recent business highlights and anticipated milestones for 2021, indicating ongoing strategic progress beyond these reimbursement achievements.

Key Highlights

1BeiGene's key medicines, including Tislelizumab, BRUKINSA® (zanubrutinib), and XGEVA® (denosumab), will be included in China's National Reimbursement Drug List (NRDL) effective March 1, 2021.
2The NRDL inclusion is expected to significantly enhance patient access to these innovative therapies within China's public medical insurance system.
3Negotiated reimbursement prices (NRDL payment standards) have been set for Tislelizumab (RMB 2,180 per 100mg), BRUKINSA® (RMB 99 per 80mg), and XGEVA® (RMB 1,060 per 120mg).
4Tislelizumab is indicated for classical Hodgkin’s lymphoma and urothelial carcinoma.
5BRUKINSA® is indicated for mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.
6XGEVA® is indicated for giant cell tumor of the bone.
7The company also provided updates on its fourth quarter 2020 financial results and business highlights, with further details expected in the referenced press release.

BeOne Medicines Ltd. 8-K Report, Financial Results (Feb 25, 2021)

Summary

Key Highlights

Frequently Asked Questions